Although studies have shown a rising statistic of resistance to T-DM1, particularly through continued trastuzumab resistance and altered drug payload internalization and intracellular release [185], ADCs remain a strong and viable treatment for drug-resistant HER2+ BC due to their immunomodulatory effects. This evidence concerns the gene ERBB2 and breast cancer.